Lumos Pharma Inc

Lumos Pharma — Q2 2021 Earnings Presentation

9 slides from Lumos Pharma's earnings presentation, Aug 5, 2021

  1. Slide 1: Second Quarter 2021

    1 Second Quarter 2021 August 5, 2021

  2. Slide 2: Forward Looking Statements

    2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. (the “Company”) that involve substantial risks and uncertainties. All such statements contained in this presentation are forward-looking statements within the meaning of The Private Securities Li

  3. Slide 3: Agenda

    3 Agenda • Lisa Miller, Senior Director of Investor Relations • Rick Hawkins, Chief Executive Officer & Chairman • John McKew, PhD, President & Chief Scientific Officer • Lori Lawley, Chief Financial Officer • David B. Karpf, MD, Chief Medical Officer

  4. Slide 4: Continuing to Enhance the Leadership Team

    4 Continuing to Enhance the Leadership Team • August 3rd -- Hired top tier, seasoned endocrinologist as CMO o David Karpf, MD, CMO – Previously VP, Clinical Development, Ascendis, current Adjunct Clinical Professor, Division of Endocrinology, at Stanford University School of Medicine, where he sees

  5. Slide 5: LUM-201 Program Pipeline

    5 LUM-201 Program Pipeline Study Pre-Clinical Phase 1 Phase 2 Phase 3 Status LUM-201 (Ibutamoren) In PGHD Phase 2 Ongoing Phase 2 trial with 6-month data readout expected in second half of 2023 Long-term extension Long-term extension study for OraGrowtH210, OraGrowtH212, and future OraGrowtH Trials

  6. Slide 6: OraGrowtH210 Trial: Phase 2 Trial in PGHD

    6 OraGrowtH210 Trial: Phase 2 Trial in PGHD *Proposed protocol amendment N=20 Daily rhGH injection N=20 LUM-201: 3.2 mg/kg/day N=20 LUM-201: 1.6 mg/kg/day N=20 LUM-201: 0.8 mg/kg/day • n = 80 • PEM(+) PGHD patients • Inclusion: stim GH ≥ 5ng/ml and baseline IGF-1 > 30ng/ml • rhGH treatment naïve • 4

  7. Slide 7: OraGrowtH212 Trial: Pharmacokinetic / Pharmacodynamic Trial in PGHD

    7 • n = 24 • Open-label study • PGHD patients • rhGH-treatment naïve • 12-month dosing • Single, specialized clinical site • Q10 minute sampling for 12 hours OraGrowtH212 Trial: Pharmacokinetic / Pharmacodynamic Trial in PGHD Goals: • Confirm prior PK/PD data in adults & subset of Merck 020 trial •

  8. Slide 8: Secure Cash Position

    8 Secure Cash Position Metric Position Cash balance June 30, 2021 $107.7 million Strong financial position Cash runway through primary outcome data for OraGrowtH210 & OraGrowtH212 Trials Shares outstanding as of June 30, 2021 ~ 8.3 million Cash balance to support current operations through primary o

  9. Slide 9: Investment Highlights

    9 Investment Highlights PGHD = Pediatric Growth Hormone Deficiency * USA, Germany, France, Italy, Spain, UK, Japan (Grandview Research, Growth Hormone Market Forecast, 2019) Late-stage Rare Disease Asset Pipeline in a Product Experienced Management Solid Financial Position • Novel oral therapeutic a

Lumos Pharma — Q2 2021 Earnings Presentation on 6ix